Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin最新文献

{"title":"Omicron BA.2.75 variant is efficiently neutralised following BA.1 and BA.5 breakthrough infection in vaccinated individuals, Israel, June to September 2022.","authors":"Nofar Atari,&nbsp;Limor Kliker,&nbsp;Neta Zuckerman,&nbsp;Bayan Abd Elkader,&nbsp;Yael Weiss-Ottolenghi,&nbsp;Ella Mendelson,&nbsp;Yitshak Kreiss,&nbsp;Gili Regev-Yochay,&nbsp;Michal Mandelboim","doi":"10.2807/1560-7917.ES.2022.27.44.2200785","DOIUrl":"https://doi.org/10.2807/1560-7917.ES.2022.27.44.2200785","url":null,"abstract":"<p><p>We evaluated neutralising antibody titres against wild type (WT) SARS-CoV-2 and four Omicron variants (BA.1, BA.2, BA.5 and BA.2.75) in fully vaccinated (three doses of Comirnaty vaccine) healthcare workers (HCW) in Israel who had breakthrough BA.1/BA5 infections. Omicron breakthrough infections in vaccinated individuals resulted in increased neutralising antibodies against the WT and Omicron variants compared with vaccinated uninfected HCW. HCW who recovered from BA.1 or BA.5 infections showed similar neutralising antibodies levels against BA.2.75.</p>","PeriodicalId":520613,"journal":{"name":"Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin","volume":" ","pages":""},"PeriodicalIF":19.0,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9635020/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40444242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antibiotic resistance surveillance of <i>Klebsiella pneumoniae</i> complex is affected by refined MALDI-TOF identification, Swiss data, 2017 to 2022.","authors":"Irene Katharina Voellmy,&nbsp;Claudia Lang,&nbsp;Michael Gasser,&nbsp;Andreas Kronenberg","doi":"10.2807/1560-7917.ES.2022.27.45.2200104","DOIUrl":"https://doi.org/10.2807/1560-7917.ES.2022.27.45.2200104","url":null,"abstract":"<p><p>BackgroundModern laboratory methods such as next generation sequencing and MALDI-TOF allow identification of novel bacterial species. This can affect surveillance of infections and antimicrobial resistance. From 2017, increasing numbers of medical microbiology laboratories in Switzerland differentiated <i>Klebsiella variicola</i> from <i>Klebsiella pneumoniae</i> complex using updated MALDI-TOF databases, whereas many laboratories still report them as <i>K. pneumoniae</i> or <i>K. pneumoniae</i> complex.AimOur study explored whether separate reporting of <i>K. variicola</i> and the <i>Klebsiella pneumoniae</i> complex affected the ANRESIS surveillance database.MethodsWe analysed antibiotic susceptibility rates and specimen types of <i>K. variicola</i> and non-<i>K. variicola</i>-<i>K. pneumoniae</i> complex isolates reported by Swiss medical laboratories to the ANRESIS database (Swiss Centre for Antibiotic Resistance) from January 2017 to June 2022.ResultsAnalysis of Swiss antimicrobial resistance data revealed increased susceptibility rates of <i>K. variicola</i> compared with species of the <i>K. pneumoniae</i> complex other than <i>K. variicola</i> in all six antibiotic classes tested. This can lead to underestimated resistance rates of <i>K. pneumoniae</i> complex in laboratories that do not specifically identify <i>K. variicola</i>. Furthermore, <i>K. variicola</i> strains were significantly more often reported from blood and primarily sterile specimens than isolates of the <i>K. pneumoniae</i> complex other than <i>K. variicola,</i> indicating increased invasiveness of <i>K. variicola</i>.ConclusionOur data suggest that refined differentiation of the <i>K. pneumoniae</i> complex can improve our understanding of its taxonomy, susceptibility, epidemiology and clinical significance, thus providing more precise information to clinicians and epidemiologists.</p>","PeriodicalId":520613,"journal":{"name":"Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin","volume":" ","pages":""},"PeriodicalIF":19.0,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9650708/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40462452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Autochthonous dengue in mainland France, 2022: geographical extension and incidence increase.","authors":"Amandine Cochet,&nbsp;Clémentine Calba,&nbsp;Frédéric Jourdain,&nbsp;Gilda Grard,&nbsp;Guillaume André Durand,&nbsp;Anne Guinard,&nbsp;Harold Noël,&nbsp;Marie-Claire Paty,&nbsp;Florian Franke","doi":"10.2807/1560-7917.ES.2022.27.44.2200818","DOIUrl":"https://doi.org/10.2807/1560-7917.ES.2022.27.44.2200818","url":null,"abstract":"<p><p>France faced an unusual situation of dengue transmission in 2022, with 65 autochthonous cases spread over nine transmission events by 21 October. This exceeded the number of cases observed during the entire period 2010 to 2021. Six of these events occurred in departments that had never experienced autochthonous dengue transmission. We provide an update of dengue surveillance data in mainland France in 2022. The multiplication of transmission events calls for continuous adaption of preparedness and response to arbovirus-related risks.</p>","PeriodicalId":520613,"journal":{"name":"Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin","volume":" ","pages":""},"PeriodicalIF":19.0,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9635021/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40446702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ongoing toxin-positive diphtheria outbreaks in a federal asylum centre in Switzerland, analysis July to September 2022.","authors":"Jacob Kofler,&nbsp;Alban Ramette,&nbsp;Patricia Iseli,&nbsp;Lea Stauber,&nbsp;Jens Fichtner,&nbsp;Sara Droz,&nbsp;Annina Zihler Berner,&nbsp;Anna Bettina Meier,&nbsp;Michelle Begert,&nbsp;Sabine Negri,&nbsp;Anne Jachmann,&nbsp;Peter Michael Keller,&nbsp;Cornelia Staehelin,&nbsp;Barbara Grützmacher","doi":"10.2807/1560-7917.ES.2022.27.44.2200811","DOIUrl":"https://doi.org/10.2807/1560-7917.ES.2022.27.44.2200811","url":null,"abstract":"<p><p>Two diphtheria outbreaks occurred in a Swiss asylum center from July to October 2022, one is still ongoing. Outbreaks mainly involved minors and included six symptomatic respiratory diphtheria cases requiring antitoxin. Phylogenomic analyses showed evidence of imported and local transmissions of toxigenic strains in respiratory and skin lesion samples. Given the number of cases (n = 20) and the large genetic diversity accumulating in one centre, increased awareness and changes in public health measures are required to prevent and control diphtheria outbreaks.</p>","PeriodicalId":520613,"journal":{"name":"Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin","volume":" ","pages":""},"PeriodicalIF":19.0,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9635023/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40446704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SARS-CoV-2 spike IgG titres up to 137 days following Comirnaty mRNA COVID-19 vaccination, Israel, February to May 2021.","authors":"Tal Patalon,&nbsp;Shay Ben Moshe,&nbsp;Asaf Peretz,&nbsp;Ami Neuberger,&nbsp;Licita Schreiber,&nbsp;Rachel Lazar,&nbsp;Lia Supino-Rosin,&nbsp;Galit Perez,&nbsp;Miri Mizrahi-Reuveni,&nbsp;Sivan Gazit","doi":"10.2807/1560-7917.ES.2022.27.40.2100703","DOIUrl":"https://doi.org/10.2807/1560-7917.ES.2022.27.40.2100703","url":null,"abstract":"<p><p>BackgroundData regarding the long-term protection afforded by vaccination for the SARS-CoV-2 infection are essential for allocation of scarce vaccination resources worldwide.MethodsWe conducted a retrospective cohort study aimed at studying the kinetics of IgG antibodies against SARS-CoV-2 in COVID-19-naïve patients fully vaccinated with two doses of Comirnaty mRNA COVID-19 vaccine. Geometric mean concentrations (GMCs) of antibody levels were reported. Linear models were used to assess antibody levels after full vaccination and their decline over time.ResultsThe study included 4,740 patients and 5,719 serological tests. Unadjusted GMCs peaked 28-41 days after the first dose at 10,174 AU/mL (95% CI: 9,211-11,237) and gradually decreased but remained well above the positivity cut-off. After adjusting for baseline characteristics and repeated measurements, the antibodies half-life time was 34.1 days (95% CI: 33.1-35.2), and females aged 16-39 years with no comorbidities had antibody levels of 20,613 AU/mL (95% CI: 18,526-22,934) on day 28 post-first-dose. Antibody levels were lower among males (0.736 of the level measured in females; 95% CI: 0.672-0.806), people aged 40-59 (0.729; 95% CI: 0.649-0.818) and ≥ 60 years (0.452; 95% CI: 0.398-0.513), and patients having haematological (0.241; 95% CI: 0.190-0.306) or solid malignancies (0.757; 95% CI: 0.650-0.881), chronic kidney disease with glomerular filtration rate (GFR) ≥ 30 (0.434; 95% CI: 0.354-0.532) or with GFR < 30 mL/min (0.176; 95% CI: 0.109-0.287), and immunosuppression (0.273; 95% CI: 0.235-0.317). Body mass index, cardiovascular disease, congestive heart failure, chronic obstructive pulmonary disease, diabetes and inflammatory bowel diseases were not associated with antibody levels.ConclusionsVaccination with two doses resulted in persistently high levels of antibodies (≥ cut-off of 50 AU/mL) up to 137 days post-first-dose. Risk factors for lower antibody levels were identified.</p>","PeriodicalId":520613,"journal":{"name":"Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin","volume":" ","pages":""},"PeriodicalIF":19.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540524/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33493753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum for Euro Surveill. 2021;27(42).","authors":"","doi":"10.2807/1560-7917.ES.2022.27.43.221027e","DOIUrl":"https://doi.org/10.2807/1560-7917.ES.2022.27.43.221027e","url":null,"abstract":"","PeriodicalId":520613,"journal":{"name":"Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin","volume":" ","pages":""},"PeriodicalIF":19.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9615413/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40434844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mediterranean spotted fever-like illness caused by <i>Rickettsia sibirica mongolitimonae</i>, North Macedonia, June 2022.","authors":"Dejan Jakimovski,&nbsp;Sofija Mateska,&nbsp;Verica Simin,&nbsp;Ivana Bogdan,&nbsp;Dragana Mijatović,&nbsp;Agustín Estrada-Peña,&nbsp;Lourdes Mateos-Hernández,&nbsp;Angélique Foucault-Simonin,&nbsp;Sara Moutailler,&nbsp;Alejandro Cabezas-Cruz,&nbsp;Pavle Banović","doi":"10.2807/1560-7917.ES.2022.27.42.2200735","DOIUrl":"https://doi.org/10.2807/1560-7917.ES.2022.27.42.2200735","url":null,"abstract":"<p><p>Mediterranean spotted fever-like illness (MSF-like illness) is a tick-borne disease caused by <i>Rickettsia sibirica mongolitimonae</i> first reported in France more than 25 years ago. Until today, more than 50 cases of MSF-like illness have been reported in different regions of Europe and Africa, highlighting variable clinical manifestation. Here we report a case of MSF-like illness following a bite from a <i>Hyalomma</i> tick in the Skopje region of North Macedonia.</p>","PeriodicalId":520613,"journal":{"name":"Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin","volume":" ","pages":""},"PeriodicalIF":19.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9585876/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40560909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"External quality assessment of SARS-CoV-2 serology in European expert laboratories, April 2021.","authors":"Ramona Mögling,&nbsp;Francesca Colavita,&nbsp;Johan Reimerink,&nbsp;Angeliki Melidou,&nbsp;Katrin Leitmeyer,&nbsp;Maria Keramarou,&nbsp;Daniele Lapa,&nbsp;Massimo Francalancia,&nbsp;Jean-Luc Murk,&nbsp;Ann Vossen,&nbsp;Fabrizio Carletti,&nbsp;Boris Hogema,&nbsp;Adam Meijer,&nbsp;Liesbet Deprez,&nbsp;Antonino di Caro,&nbsp;Concetta Castilletti,&nbsp;Chantal Bem Reusken","doi":"10.2807/1560-7917.ES.2022.27.42.2101057","DOIUrl":"https://doi.org/10.2807/1560-7917.ES.2022.27.42.2101057","url":null,"abstract":"<p><p>BackgroundCountries worldwide are focusing to mitigate the ongoing SARS-CoV-2 pandemic by employing public health measures. Laboratories have a key role in the control of SARS-CoV-2 transmission. Serology for SARS-CoV-2 is of critical importance to support diagnosis, define the epidemiological framework and evaluate immune responses to natural infection and vaccine administration.AimThe aim of this study was the assessment of the actual capability among laboratories involved in sero-epidemiological studies on COVID-19 in EU/EEA and EU enlargement countries to detect SARS-CoV-2 antibodies through an external quality assessment (EQA) based on proficiency testing.MethodsThe EQA panels were composed of eight different, pooled human serum samples (all collected in 2020 before the vaccine roll-out), addressing sensitivity and specificity of detection. The panels and two EU human SARS-CoV-2 serological standards were sent to 56 laboratories in 30 countries.ResultsThe overall performance of laboratories within this EQA indicated a robust ability to establish past SARS-CoV-2 infections via detection of anti-SARS-CoV-2 antibodies, with 53 of 55 laboratories using at least one test that characterised all EQA samples correctly. IgM-specific test methods provided most incorrect sample characterisations (24/208), while test methods detecting total immunoglobulin (0/119) and neutralising antibodies (2/230) performed the best. The semiquantitative assays used by the EQA participants also showed a robust performance in relation to the standards.ConclusionOur EQA showed a high capability across European reference laboratories for reliable diagnostics for SARS-CoV-2 antibody responses. Serological tests that provide robust and reliable detection of anti-SARS-CoV-2 antibodies are available.</p>","PeriodicalId":520613,"journal":{"name":"Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin","volume":" ","pages":""},"PeriodicalIF":19.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9585882/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40672688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antimicrobial-resistant gonorrhoea: the national public health response, England, 2013 to 2020.","authors":"Rachel Merrick,&nbsp;Michelle Cole,&nbsp;Rachel Pitt,&nbsp;Qudsia Enayat,&nbsp;Zdravko Ivanov,&nbsp;Michaela Day,&nbsp;Suzy Sun,&nbsp;Katy Sinka,&nbsp;Neil Woodford,&nbsp;Hamish Mohammed,&nbsp;Helen Fifer","doi":"10.2807/1560-7917.ES.2022.27.40.2200057","DOIUrl":"https://doi.org/10.2807/1560-7917.ES.2022.27.40.2200057","url":null,"abstract":"<p><p><i>Neisseria gonorrhoeae</i> has developed resistance to all antimicrobials used to treat gonorrhoea, and the emergence of ceftriaxone-resistant strains threatens the last-line option for empirical treatment. The 2013 Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) Action Plan recommended measures to delay the spread of antimicrobial resistance (AMR) in <i>N. gonorrhoeae</i> in England. We reviewed trends in gonococcal AMR since then and the experience of implementing the Action Plan's recommendations to respond to incidents of resistant <i>N. gonorrhoeae</i>. Between 2013 and 2019, diagnoses of gonorrhoea in England rose by 128% to 70,922, the largest annual number ever reported. Over this period, <i>N. gonorrhoeae</i> isolates have become less susceptible to azithromycin (minimum inhibitory concentration > 0.5 mg/L), increasing from 4.7% in 2016 to 8.7% in 2020; this led to a change in first-line treatment for gonorrhoea in the United Kingdom (UK) from dual therapy (ceftriaxone/azithromycin) to ceftriaxone monotherapy in 2019. We also detected the first global treatment failure for pharyngeal gonorrhoea with a dual-therapy regimen (ceftriaxone/azithromycin), followed by an additional six ceftriaxone-resistant strains. Continued engagement of sexual health clinicians and laboratories with the UK Health Security Agency (UKHSA) is essential for the timely detection of <i>N. gonorrhoeae</i> strains with ceftriaxone resistance and to rapidly contain transmission of these strains within England.</p>","PeriodicalId":520613,"journal":{"name":"Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin","volume":" ","pages":""},"PeriodicalIF":19.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540523/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33493755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preparing Europe for future health threats and crises ─ the European Medicines Agency; ensuring safe and effective medicines and medical devices.","authors":"Emer Cooke","doi":"10.2807/1560-7917.ES.2022.27.42.2200798","DOIUrl":"https://doi.org/10.2807/1560-7917.ES.2022.27.42.2200798","url":null,"abstract":"Despite the absence of an explicit legal mandate and appropriate resources, EMA quickly introduced a structure to coordinate activities and established processes which were crucial for an effective EU-wide response. For example, EMA coordinated the exchange of information and actions to identify and mitigate medicine shortages between EU countries when global pharmaceutical supply chains were disrupted almost overnight because of border closures and lockdowns and there was an increased demand for medicines, particularly in the intensive care unit setting. However, it became clear early in the pandemic that EMA needed stronger legal tools to help ensure the availability of medicinal products and medical devices and to support the development of new therapeutics to protect the health of Europeans in times of crisis.","PeriodicalId":520613,"journal":{"name":"Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin","volume":" ","pages":""},"PeriodicalIF":19.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9585881/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40560908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}